The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
H | Systemic hormonal preparations, excl. Sex hormones and insulins | |
2
|
H01 | Pituitary and hypothalamic hormones and analogues | |
3
|
H01A | Anterior pituitary lobe hormones and analogues | |
4
|
H01AC | Somatropin and somatropin agonists | |
5
|
H01AC07 |
| Active Ingredient |
|---|
|
Somapacitan is a long-acting recombinant human growth hormone derivative. The mechanism of action of somapacitan is either directly via the GH-receptor and/or indirectly via IGF-I produced in tissues throughout the body, but predominantly by the liver. When growth hormone deficiency is treated with somapacitan a normalisation of body composition (i.e., decreased body fat mass, increased lean body mass) and of metabolic action is achieved. |
| Document | Type | Information Source | |
|---|---|---|---|
| SOGROYA Solution for injection | MPI, EU: SmPC | European Medicines Agency (EU) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.